Clinical trial · Observational
Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
NCT06945432CI-TRIAL-00088939completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to compare the diagnostic efficacy of 68Ga-CTR-FAPI PET/CT and 18F-FDG PET/CT in various malignant tumors
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| FAPI | — | UNRESOLVED | — |
| FDG PET/CT | — | UNRESOLVED | — |
| PET / CT | — | UNRESOLVED | — |
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Lesion uptake
- timeFrame
- 1 day
- description
- Standardized uptake value (SUV)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: (a) Age ≥ 18 years old; (b) Suspected or newly diagnosed malignant tumors, evaluating the therapeutic effect of the tumor, or discovering recurrence/metastasis; (c) Obtain approval from oncologists and agree to undergo 18F-FDG and 68Ga-CTR-FAPI PET/CT scans within one week. Exclusion Criteria: (a) Pregnancy or lactation period; (b) Claustrophobia. (c) Serious health problems: such as severe heart, liver and kidney dysfunction, diseases that affect the metabolism or clearance of imaging agents.
References
Publications (0)
Data not yet available
No reference posted for this study.